Nota de prensa

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reported financial results for the quarter and year ended December 31, 2018.

On January 1, 2018, IQVIA adopted ASC 606 “Revenue from Contracts with Customers” as required by the Financial Accounting Standards Board. Under this standard, IQVIA recognizes revenue in the Research & Development Solutions segment on a percentage of completion basis. Additionally, ASC 606 requires that service revenue and reimbursed expense revenue be consistently presented as one line on the income statement. Unless stated otherwise, all financial information that follows has been provided under ASC 606.

This will be the last reminder of the accounting change, as following the fourth quarter, IQVIA has passed the anniversary of ASC 606 adoption, which will be the basis for all reporting going forward.

Fourth-Quarter 2018 Operating Results
Revenue for the fourth quarter of $2,688 million increased 6.6 percent on a reported basis and 8.1 percent at constant currency, compared to the fourth quarter of 2017. Technology & Analytics Solutions (TAS) revenue of $1,127 million grew 8.8 percent reported and 10.9 percent at constant currency. Research & Development Solutions (R&DS) revenue of $1,368 million grew 7.8 percent reported and 8.7 percent at constant currency. Contract Sales & Medical Solutions (CSMS) revenue of $193 million declined 10.6 percent reported and 8.8 percent at constant currency.

Fourth-quarter 2018 Adjusted EBITDA of $583 million increased 10.8 percent reported and 9.7 percent at constant currency, compared to the fourth quarter of 2017. GAAP net income was $69 million and GAAP diluted earnings per share was $0.34. Adjusted Net Income of $307 million grew 17.6 percent, and Adjusted Diluted Earnings per Share of $1.50 grew 23.0 percent.

“We closed 2018 with a strong quarter, and delivered results at the high end of, or above our financial targets, capping a year of outstanding performance,” said Ari Bousbib, chairman and CEO of IQVIA. “Our clinical development team had another record quarter of contracted net new business, and our technology team continued to add impressive new client wins for our OCE SaaS platform. As we enter the third year of our merger integration, we are pleased to see the beginning of top line acceleration in both our R&DS and TAS businesses. We are also encouraged that our CSMS business is showing positive signs of stabilization as we head into 2019. Across all our businesses, the IQVIA team is building momentum to further accelerate growth beyond 2019.”

Full-Year 2018 Operating Results
Revenue of $10,412 million for the full year of 2018 increased 7.3 percent reported and 6.8 percent at constant currency, compared to the full year of 2017. TAS revenue of $4,137 million grew 12.4 percent reported and 12.1 percent at constant currency. R&DS revenue of $5,465 million grew 7.1 percent reported and 6.5 percent at constant currency. CSMS revenue of $810 million declined 11.5 percent reported and 12.2 percent at constant currency.

R&DS contracted backlog, including reimbursed expenses, was $17.13 billion at December 31, 2018. The company expects approximately $4.8 billion of this backlog to convert to revenue in the next twelve months. For comparability during 2018, IQVIA is reporting R&DS net new business on a contracted basis excluding reimbursed expenses. Under this approach, R&DS contracted net new business of $5.85 billion for the twelve months ended December 31, 2018 grew 28.9 percent compared to the twelve months ended December 31, 2017. R&DS contracted net new business for the quarter ending December 31, 2018 was $1.7 billion, representing a contracted book-to-bill ratio (excluding reimbursed expenses) of 1.7x for the fourth quarter of 2018.

For the full year of 2018, Adjusted EBITDA of $2,224 million increased 10.6 percent reported and 9.9 percent at constant currency, compared to the full year of 2017. GAAP net income was $259 million and GAAP diluted earnings per share was $1.24. Adjusted Net Income of $1,156 million for the full year of 2018 grew 14.0 percent, and Adjusted Diluted Earnings per Share of $5.55 grew 22.0 percent.

Financial Position
As of December 31, 2018, cash and cash equivalents were $891 million and debt was $11,007 million, resulting in net debt of $10,116 million. At the end of the fourth quarter of 2018, IQVIA’s Gross Leverage Ratio was 4.9 times, and Net Leverage Ratio was 4.5 times, trailing twelve month Adjusted EBITDA.

Share Repurchase
The company repurchased $604 million of its common stock during the fourth quarter of 2018, including a repurchase of $247 million from IQVIA’s remaining private equity sponsors towards the end of the quarter. Full-year 2018 share repurchases totaled $1.4 billion.

On February 13, 2019, the IQVIA board approved an increase of the share repurchase authorization by $2.0 billion, bringing remaining authorizations to approximately $2.3 billion.

Full-Year 2019 Guidance
IQVIA expects full-year 2019 revenue between $10,900 million and $11,125 million, Adjusted EBITDA between $2,375 million and $2,425 million and Adjusted Diluted Earnings per Share between $6.20 and $6.40. Full-year 2019 segment revenue guidance is as follows:

First-Quarter 2019 Guidance
IQVIA expects first-quarter 2019 revenue between $2,630 million and $2,680 million, Adjusted EBITDA between $575 million and $590 million and Adjusted Diluted Earnings per Share between $1.48 and $1.53.

This financial guidance assumes foreign currency exchange rates at January 1, 2019 remain in effect for the remainder of the year.

Webcast & Conference Call Details
IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its fourth quarter and full year 2018 financial results and 2019 guidance. To participate, please dial 1-800-919-0370 in the United States and Canada or +1-212-231-2935 outside the United States approximately 15 minutes before the scheduled start of the call. The conference call and a presentation will be accessible live via webcast on the Investors section of the IQVIA website at http://ir.iqvia.com. An archived replay of the webcast will be available online at http://ir.iqvia.com after 1:00 p.m. Eastern Time today.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries.

Cautionary Statements Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our 2019 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to changes in accounting standards, including the impact of the changes to the revenue recognition standards; general economic conditions in the markets in which we operate, including financial market conditions and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. For a further discussion of the risks relating to the combined company’s business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2017, filed with the SEC, as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.

Note on Non-GAAP Financial Measures
Non-GAAP results, such as Adjusted EBITDA, Adjusted Net Income, and Adjusted Diluted EPS are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. Definitions and reconciliations of non-GAAP measures to the most directly comparable GAAP measures are provided within the schedules attached to this release. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

Our 2019 guidance measures (other than revenue) are provided on a non-GAAP basis because the company is unable to reasonably predict certain items contained in the GAAP measures. Such items include, but are not limited to, acquisition and integration related expenses, restructuring and related charges, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

Click here to subscribe to Mobile Alerts for IQVIA.

IQVIAFIN